The gene encoding myopodin, an actin binding protein, is commonly deleted in invasive, but not in indolent, prostate cancers. There are conflicting reports on the effects of myopodin expression on prostate cancer cell migration and invasion. The recent recognition that myopodin is expressed as four different isoforms further complicates our understanding of how this potentially important invasive prostate cancer biomarker affects tumor cell migration and invasion. We now show that myopodin affects the chemokinetic, rather than the chemotactic, properties of PC3 prostate cancer cells. Furthermore, all myopodin isoforms can either increase or decrease PC3 cell migration in response to different chemokinetic stimuli. These migration properties were reflected by differences in cell morphology and the relative dependence on Rho-ROCK signaling pathways induced by the environmental stimuli. Truncation analysis determined that a unique 9-residue C-terminal sequence in the shortest isoform and the conserved, PDZ domain-containing N-terminal region of the long isoforms both contribute to the ability of myopodin to alter the response of PC3 cells to chemokinetic stimuli. Matrigel invasion assays also indicated that myopodin primarily affects the migration, rather than the invasion, properties of PC3 cells. The correlation between loss of myopodin expression and invasive prostate cancer therefore reflects complex myopodin interactions with pathways that regulate the cellular migration response to diverse signals that may be present in a tumor microenvironment.
Introduction
Biomarkers that accurately predict whether localized prostate cancer will remain indolent or become invasive could inform decisions on the best course of therapy and improve the quality of life of prostate cancer patients (1) . Myopodin represents one such biomarker. A screen for gene deletions in human prostate cancer tissues identified a frequently deleted region encompassing locus 4q26 (2) . This region, which contains the gene encoding myopodin (also referred to as synaptopodin 2), was partially or completely deleted in >92% of the invasive prostate cancer tissues. Results further indicated a 78% deletion coincidence with highly invasive tumors, with only 7% of minimally invasive tumors containing such deletions (2) . Complete loss of myopodin expression also correlates with a >86% incidence of prostate cancer relapse (3) . Increased cytoplasmic expression of myopodin has also been associated with invasive bladder cancer (4) , and the methylation-dependent epigenetic silencing of myopodin gene expression is a prognosticator of invasive colon cancer (5) . However, we know relatively little about why myopodin loss correlates with tumor development.
There are only a limited number of reports investigating how human myopodin affects prostate cancer cell invasion. Ectopic expression of myopodin suppresses PC3 prostate cancer cell proliferation, invasion and colony formation in vitro, and decreases prostate tumor growth, metastasis and mortality in xenografted SCID mice (6) (7) (8) , consistent with myopodin functioning to suppress tumor cell invasion. In contrast, RNAi knockdown of human myopodin expression decreases PC3 cell migration and invasion (9) , whereas ectopic expression of the mouse myopodin homolog increased invasion of HEK293T cells and mouse C2C12 myoblasts (10) . Human myopodin has also been reported to colocalize with actin filaments in prostate cancer cells (11) , and the mouse, rabbit and chicken myopodin homologs promote actin polymerization and actin bundle formation (12) (13) (14) (15) . Myopodin may, therefore, alter cell migration and invasion via effects on actin cytoskeletal dynamics, although this has not been shown.
The discovery of several different myopodin isoforms adds an additional level of complexity when considering myopodin function. Prior to 2008, only one isoform of human myopodin was known. Three additional isoforms were recently identified that arise via differential splicing (11) . These transcripts encode predicted myopodin proteins of 1093, 1109 or 1261 residues (isoforms MYO1, MYO2 and MYO3, respectively) that are identical over their N-terminal 1084 residues and contain unique C-termini of 9, 25 or 176 residues ( Figure 1 ). The studies defining myopodin as a tumor suppressor used a 698-residue protein, which represents an N-terminal truncation of MYO1 (2, (6) (7) (8) . We refer to this truncated isoform as △N-MYO1, which was recently shown to arise in human skeletal muscle cells via transcription from an alternate promoter located in exon 3 (16) . This 395-residue N-terminal truncation removes the PDZ domain (a common protein-protein interaction motif) contained in the longer myopodin isoforms. The previously identified binding sites for actin, filamin and α-actinin (15, 16) , as well as binding sites for zyxin and integrin-linked kinase (7, 8) are in the conserved region present in all four myopodin isoforms. Whether any of these isoforms exert differential effects on prostate cancer cell invasion is unknown.
The basis for the differential effects of myopodin on prostate cancer cell migration and invasion has not been investigated, and the roles of the different myopodin isoforms in this process are unknown. Using transwell migration assays, we determined that all of the myopodin isoforms can either promote or suppress the motility of PC3 cells, depending on the nature of the migration stimulus. All of the myopodin isoforms exert only modest effects on PC3 cell invasion but substantially alter the chemokinetic response of cells. These motility responses are influenced by both the N-and C-terminal regions of myopodin, and reflect the differential activation of Rho-ROCK signaling pathways by the different stimuli and by myopodin.
Materials and methods

Cells and reagents
PC3 and NIH 3T3 cells were provided by David Hoskin (Dalhousie University). Cells were maintained in high glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen) at 37°C in 5% CO 2 . The anti-myopodin antibody (Abcam) recognizes residues 566-585, which is located in the conserved region present in all myopodin isoforms. Horseradish peroxidase-conjugated anti-rabbit antibody (Jackson ImmunoResearch), anti-myosin light chain and phosphorylated myosin light chain antibodies (Cell Signaling), anti-Rho A antibody (Cell Signaling), Y-27632 (Sigma), puromycin (Invitrogen), Alexa555-conjugated Phalloidin (Invitrogen), Sequabrene (Sigma), restriction enzymes (NEB biolabs), Matrigel (BD Bioscience) and NSC23766 (EMD Millipore) were purchased from the indicated commercial sources.
Molecular cloning
MYO1, MYO2 and MYO3 in the pcDNA3.1/V5-His-TOPO vector were kindly provided by Jan Gettemans (Ghent University, Belgium). All myopodin isoforms were amplified with PfuUltra High Fidelity DNA polymerase (Agilent Biotechnologies) and subcloned into the pBMN retroviral vector. ΔN-MYO1 was subcloned from the MYO1 template using a forward Abbreviations: BSA, bovine serum albumin; CM, conditioned medium; FBS, fetal bovine serum; MLC, myosin light chain; MYO, myopodin.
Carcinogenesis vol.33 no.11 pp.2100-2107, 2012 doi:10.1093/carcin/bgs268 Advance Access publication August 21, 2012 primer that removed the coding sequence for the N-terminal 395 residues. The full-length myopodin (MYO1, MYO2, MYO3 and ΔN-MYO1) and truncated myopodin constructs (ΔN/ΔC-MYO and ΔC-MYO) were PCR amplified with primers containing BamHI and SalI sites and subcloned into the BamHI and XhoI sites in the pBMN retroviral vector.
Retroviral transduction system
Myopodin constructs in the pBMN vector were transfected into Phoenix cells, a retrovirus packaging cell line, using Polyethyleneimine (Polysciences). After 48 h, supernatants were collected and filtered through a 0.45 µm filter. Sequabrene (4 µg/ml) was added to the viral supernatant prior to infection of PC3 cells. Cells were transduced with the indicated retrovirus vectors for 24 h and cultured for 24 h with fresh growth medium before selection with puromycin (1 µg/ml) for 3 days. Dead cells and debris were periodically removed by refeeding the monolayers with the selection medium.
Western blotting
Cells were lysed on ice for 20 min using RIPA buffer (Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate) containing a protease inhibitor cocktail (Pierce), and the lysate was sonicated using multiple short bursts with a stainless steel probe sonicator. Samples were centrifuged at 11 000g for 10 min at 4°C, and the supernatant protein concentrations were determined using the Bradford protein assay (Bio-Rad). Concentrated protein sample buffer (5% sodium dodecyl sulfate, 0.25% bromophenol blue and 50% glycerol) was added to the cell lysate (1:4 ratio), and supplemented with dithiothreitol (50 mM final concentration) before boiling the lysates. An equal protein load of the cell lysates were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (7.5% polyacrylamide), transferred electrophoretically onto polyvinylidene difluoride membranes, blocked with 5% milk, and the membranes were probed with a 1:2500 dilution of polyclonal anti-myopodin antibody and a 1:5000 dilution of anti-rabbit horseradish peroxidase-conjugated secondary antibody. Blots were developed using ECL-Plus reagent (GE Healthcare) and visualized on a Kodak 4000-mm Pro CCD imager.
Microscopy
PC3 cells were cultured on tissue culture treated glass coverslips (Fisher Scientific) and fixed in 3.7% formaldehyde at room temperature for 20 min, then permeabilized with 0.25% Triton X-100 in phosphate-buffered saline at room temperature for 10 min. Filamentous actin was visualized using Alexa555-conjugated phalloidin (1:40 dilution). Phalloidin-stained cells were viewed and photographed with a Zeiss Axiovert 200M fluorescence microscope. Cells were also fixed with methanol, stained with Wright-Giemsa at the indicated times, and cells were viewed and photographed with Nikon Diaphot-TMD Inverted Microscope.
Transwell migration and invasion assays
Migration and invasion assays were performed using 24-well transwell units with 8 µm porous polycarbonate membranes (BD Falcon). The top chamber was seeded with 0.75 × 10 5 cells/well and was filled with Dulbecco's modified Eagle's medium supplemented with either 0.1% bovine serum albumin (BSA) or 10% FBS, whereas the bottom chamber was filled with 10% FBS/ Dulbecco's modified Eagle's medium or NIH 3T3 conditioned medium (CM) as indicated. NIH 3T3 CM was collected from cells after 24 h of serum starvation. Y-27632 or NSC23766 was added to the top and bottom chambers at the indicated concentrations. The 10 µM concentration of Y-27632 is generally considered specific for ROCK, although protein kinase C-related kinase (PRK), another Rho effector kinase, is also inhibited in vitro at these concentrations (17) . Cells seeded on top of the insert membrane were incubated for 24 h or 12 h in the presence of FBS or NIH 3T3 CM, respectively. Following incubation, cells were fixed with methanol, stained with Giemsa or 4′,6-diamidino-2-phenylindole for 10 min, and five random fields were imaged with a 20× objective, using duplicate or triplicate filters for each sample. The average number of cells per field that transmigrated through the membrane was quantified using ImageJ software. For invasion assays, the transwell filters were coated with a thin layer (40 µl) of Matrigel before seeding the cells. The rest of the experimental procedures were the same as in the migration assay. For invasion assays, both the numbers of cells that invaded and the percent cell invasion (i.e. number of cells invading through the Matrigel/number of cells migrating through the filters × 100) are presented. The results of transwell migration and invasion assay were expressed as the mean ± SEM (standard error of the mean) of three independent studies performed in duplicate, or as the mean ± SD (standard deviation) from a representative experiment (n = 3) conducted in triplicate. Statistical significance was performed by a two-tailed Student's t-test.
Activated Rho-GTP pulldown assay
RhoA activity was examined using the RhoA activation assay Biochem kit (Cytoskeleton) according to the manufacturer's instructions. Briefly, transduced PC3 cells in 10 cm dishes were serum starved for 2 days prior to treatment with 10% FBS, and cell lysates were harvested at the indicated times. About 800 µg of each lysate were incubated with rhotekin beads for 1 h at 4°C. After washing the beads, proteins were released from the beads by boiling with protein sample buffer and analyzed by western blotting using anti-Rho A antibody.
Results
Opposing effects of myopodin on cancer cell migration under different chemoattractant conditions
Conflicting reports on whether myopodin promotes or inhibits PC3 cell migration (6, (8) (9) (10) were obtained under different chemotactic conditions, using either NIH 3T3 CM or 10% FBS as chemoattractants. To determine the contribution of different chemoattractant conditions on cell migration, PC3 cells, an invasive prostate cancer cell line expressing low levels of endogenous myopodin (6), were either mock-transduced or transduced with a retrovirus vector expressing △N-MYO1. Due to the phenotypic heterogeneity of PC3 cells, cells were cultured under selective conditions for 3 days to obtain polyclonal transduced cells. Cells were grown on transwell filters, with the upper chamber containing culture medium supplemented with 0.1% BSA and the lower chamber containing either CM or 10% FBS, and the number of cells migrating through the pores of the filter was quantified by microscopic examination of stained filters.
The inherent motility of mock-transduced PC3 cells was greatly influenced by the chemoattractant conditions, and △N-MYO1 could inhibit or enhance cell migration depending on these conditions. CM-induced migration of mock-transduced PC3 cells >5-fold more efficiently than FBS (Figure 2A and 2B). △N-MYO1 expression inhibited the response of PC3 cells to CM, decreasing the extent of cell migration by ~40% (Figure 2A and 2B). Conversely, under the weak chemoattractant conditions (i.e. 10% FBS), ectopic expression . Numbers in exon 4 indicate the total number of amino acid residues present in the isoform. The N-and C-terminal amino acid sequences present at the translational start (arrows) and stop (asterices) sites are indicated above each mRNA. The sequences encoded by the C-terminus of exon 4 are underlined and are conserved in all isoforms, followed by a number indicating the number of residues that separate this conserved sequence from the unique C-terminal sequences of the isoforms (boldface). The site recognized by the polyclonal antiserum is indicated by the arrowhead.
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of △N-MYO1 increased cell migration >4-fold (Figure 2A and 2B) . The different chemoattractants also induced distinct cell morphologies. Under FBS conditions, PC3 cells exhibited a rounded morphology, whereas cells became flattened and elongated in response to CM ( Figure 2C ), suggesting these commonly employed chemoattractants trigger distinct signaling pathways. Thus, myopodin differentially alters the response of PC3 cells to external stimuli, and can either promote or suppress cell migration depending on the nature of the stimulus.
Myopodin stimulates the chemokinetic, rather than chemotactic, response of PC3 cells to FBS
To investigate the basis for the weak migration response of PC3 cells to FBS and the ability of myopodin to promote cell motility under these conditions, the migration assays were repeated using different combinations of FBS and BSA in the upper and lower compartments of the Boyden chambers. The motility of mock-transduced PC3 cells was the same regardless of whether FBS was present in only the lower chamber, in both the upper and lower chambers, or absent from either chamber ( Figure 3A ). The same held true when the concentration of FBS in the upper and lower chambers was varied in a checkerboard transmigration assay, where △N-MYO1 stimulated cell migration to approximately the same extent in the absence or in the presence of either negative or positive gradients (Supplementary Table 1 , available at Carcinogenesis Online). Although in some experiments FBS alone modestly increased (<2-fold) the migration of mock-transduced PC3 cells (data not shown), △N-MYO1 expression increased the extent of migration >4-fold, but only when cells were also stimulated by FBS ( Figure 3A) . In PC3 cells that are activated by FBS, myopodin, therefore, promotes a chemokinetic response rather than a chemotactic response to a signaling concentration gradient.
Myopodin affects PC3 cell invasion primarily by altering cell migration
The transwell assays were repeated in the presence of Matrigel to determine the effects of myopodin on cell invasion, and both the numbers of cells that invaded and the percent cell invasion (i.e. number of cells invading through the Matrigel/number of cells migrating through the filters × 100) were determined. As in the previous transwell migration assays, the ability of PC3 cells to traverse the Matrigel was dependent on the external migration stimulus. In the case of mock-transduced PC3 cells, CM increased both the motility (Figure 2A ) and the number of cells that invaded ( Figure 3B ). CM had a greater effect on stimulating cell motility than cell invasion, resulting in ~50% decrease in the percent cell invasion ( Figure 3C ). Ectopic expression of △N-MYO1 suppressed PC3 cell migration and invasion in response to CM to approximately the same extent ( Figures  2A and 3B ), leading to a modest reduction in the percent invasion ( Figure 3C ). Conversely, 10% FBS failed to stimulate PC3 cell motility ( Figure 3A ), but ~90% of the mock-transduced PC3 cells that were motile were also invasive ( Figure 3C ), a reflection of the inherent invasiveness of this cell line. Expression of △N-MYO1 promoted cell migration in response to FBS by ~4-fold (Figures 2A and 3A) while promoting cell invasion ~3.5-fold ( Figure 3B ), resulting in an ~20% decrease in the percent invasion ( Figure 3C ). Therefore, even under conditions that differentially affect cell chemokinetic activity, myopodin expression correlates with a decrease in the percentage of the cells that can penetrate through extracellular matrix.
All human myopodin isoforms affect cell migration
The above studies, and the majority of previous studies on myopodin, used the △N-MYO1 isoform. Moreover, the siRNAs used for the knockdown studies targeted all four isoforms of myopodin (9), not just the △N-MYO1 isoform used in the ectopic expression studies (6, 8) . The three long isoforms contain a conserved N-terminal region that includes a PDZ domain that is absent from the naturally occurring △N-MYO1 isoform (16). To determine whether the different MYO isoforms exhibit similar effects on cell migration and invasion, the different isoforms were ectopically expressed in PC3 cells. All of the isoforms were expressed at similar levels as determined by western blotting using a polyclonal antiserum raised against epitopes present in the conserved exon 4 ( Figure 4A ), although the △N-MYO1 isoform appeared at higher levels in some blots (compare Figures 4A and 5B) . Western blots also detected a slower migrating ~110 kDa version of the ~80 kDa △N-MYO1 isoform, which presumably reflects an undefined posttranslational modification. When examined using the transwell migration assay, all of the isoforms modestly suppressed PC3 cell migration under CM conditions but substantially enhanced cell migration under FBS conditions at levels similar to those observed with △N-MYO1 ( Figure 4B ). All myopodin isoforms, therefore, promote or inhibit cell migration, depending on the nature of the migration stimulus.
Multiple regions of myopodin contribute to enhanced cell migration
To define regions in myopodin that alter the chemokinetic response of PC3 cells, a series of myopodin truncation constructs were created that removed the unique N-and/or C-termini present in the different isoforms ( Figure 5A ). These constructs were expressed at approximately equivalent levels in transduced PC3 cells, as determined by western blotting ( Figure 5B ). Although △C-MYO produced a single polypeptide band, as did the parental MYO3, the △N-MYO3 and △C/△N-MYO constructs expressed two versions of the myopodin protein, suggesting that sequences encoded by exons 1, 2 and the 5′-terminal part of exon 3 alter either the posttranslational modification or processing of myopodin. The naturally occurring △N-MYO1 isoform and the artificial △N-MYO3 construct both increased PC3 cell migration in response to FBS and modestly decreased migration in response to CM, to approximately the same extent as the full-length MYO1, MYO2 and MYO3 isoforms ( Figure 5C ). All of these changes were statistically significant (P < 0.05, n = 3). The presence or absence of the N-terminal PDZ domain, therefore, does not affect the ability of myopodin to regulate the cell response to chemokinetic stimuli.
The observation that MYO1, MYO2 and MYO3 all have similar effects on PC3 cell migration implies the unique C-termini present in these isoforms are not the determinants of chemokinetic regulation. To determine whether these unique C-termini are also dispensable, a C-terminal truncation was created (△C-MYO) that contained the sequences shared by all the long MYO isoforms but was lacking the unique C-termini present in each of these isoforms. The △C-MYO construct had the same statistically significant effect (P < 0.05, n = 3) on PC3 cell migration as the full-length constructs under FBS conditions ( Figure 5C ). Although results did not reach statistical significance, △C-MYO also suppressed migration under CM conditions in all three replicates of the experiment. The C-termini of the long MYO isoforms, therefore, exert little, if any, affect on regulating chemokinesis. Interestingly, whereas deletion of the C-terminal 9 residues from MYO1 had no effect on cell migration, removal of the same sequence from △N-MYO1 severely impaired the ability of this isoform to promote cell migration in the presence of FBS or to inhibit the migration induced by CM ( Figure 5C ). Thus, the conserved N-termini present in the three long myopodin isoforms and the unique C-terminus of △N-MYO1 individually contribute to the chemokinetic effects of myopodin.
Myopodin-stimulated cell migration is partially dependent on a Rho-ROCK signaling pathway
The rounded versus elongated morphologies induced by FBS and CM ( Figure 2C) were suggestive of differential activation of the Rho family of small GTPases associated with cytoskeletal dynamics and cell migration (18, 19) . Pharmacologic inhibitors were, therefore, used to explore the relative contributions of these pathways to the chemokinetic effects of myopodin. The Rho-associated coiled-coil forming serine/threonine kinase (ROCK) is a downstream effector in the Rho pathway (20) . Addition of a ROCK inhibitor (Y-27632) to the transwell migration assay abrogated the increased cell migration in response to CM, of both mock-transduced and △N-MYO1-transduced PC3 cells ( Figure 6A ) at statistically significant levels (P < 0.05, n = 3). There was no additive effect of myopodin and ROCK inhibitor on PC3 cell migration. CM, therefore, promotes PC3 cell migration by activating the Rho signaling pathway, and myopodin partially suppresses migration via its effects on activation of this pathway. Under FBS conditions, the ROCK inhibitor had no effect on the inherent migration activity of PC3 cells, but it did decrease cell migration induced by △N-MYO1 by ~40% ( Figure 6A ) at statistically significant levels (P < 0.05, n = 3). Direct examination of Rho activation under FBS conditions using a Rho-GTP pulldown assay indicated mock-transduced PC3 cells respond to FBS by modestly activating Rho, but expression of myopodin resulted in a 4-fold increase in Rho activation under these conditions ( Figure 6B ). Myopodin expression, therefore, increases activation of the Rho pathway in response to FBS, and inhibiting a downstream effector of this pathway reduces the level of myopodin-stimulated cell migration.
To further examine why the ROCK inhibitor only partially reduced the motility response of PC3 cells to myopodin expression under FBS conditions, dose-response assays were conducted on cells expressing △N-MYO1 and another myopodin isoform, MYO3. The ROCK inhibitor had no effect on the migration activity of mock-transduced PC3 cells, but it decreased both △N-MYO1-and MYO3-induced cell migration by ~40% in a dose-dependent manner ( Figure 6C ). Incomplete inhibition of ROCK activity was an unlikely explanation for the partial reduction in cell motility, since phosphorylation of the myosin light chain, a downstream target of ROCK (20) , was reduced to background levels by the ROCK inhibitor ( Figure 6D ). PC3 cell migration may also reflect activation of Rac GTPase (21) . Treatment of cells with the Rac inhibitor NSC23766, which blocks Rac-specific guanine nucleotide exchange factors (22) , did reduce the migration of mock-transduced PC3 cells, but it had the same dose-dependent effects on mock-transduced cells as it did on myopodin-transduced cells under FBS conditions (Supplementary Figure 1 , available at . For all three panels, results are reported as the mean ± SEM from three independent experiments performed in duplicate. Statistically significant differences between paired samples are indicated (*P < 0.05; **P < 0.01).
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Carcinogenesis Online). Thus, the ability of myopodin to promote PC3 cell migration in the presence of weak chemokinetic stimuli reflects activation of a Rho-ROCK signaling pathway, but additional ROCK-independent pathways that do not require Rac activation are also probably involved.
Discussion
Why loss of myopodin expression correlates with tumor invasion, and the roles of recently identified myopodin isoforms in this process, are presently unclear. There are also conflicting reports on whether myopodin affects PC3 cell migration (6, 8) , and whether myopodin suppresses or promotes cell invasion (7, 9, 10) . This study provides an explanation for these anomalies. Results indicate that myopodin alters the motility response of PC3 cells to external stimuli that differentially activate Rho/ROCK signaling pathways. Under conditions that substantially increase ROCK-dependent PC3 cell migration, myopodin partially suppresses this motility response. Conversely, myopodin can dramatically increase PC3 cell motility in the presence of a weak, external migration stimulus, a response that is mediated, at least partially, via activation of Rho/ROCK signaling pathways. Results also indicate that the effects of myopodin on cell invasion reflect changes to the chemokinetic, rather than the chemotactic, response of PC3 cells to external stimuli, and that all of the myopodin isoforms exert a similar effect on the cellular response to chemokinetic stimuli. Myopodin can, therefore, differentially regulate signaling pathways likely to be triggered by diverse signals present in a tumor microenvironment, thereby altering the invasion potential of tumor cells.
The unappreciated ability of myopodin to exert opposing affects on the response of PC3 cells to different external stimuli clarifies confusion over whether myopodin promotes or suppresses cell motility and invasion. Overexpression or RNAi knockdown of myopodin have both been reported to suppress PC3 invasion (6, 8, 9) . The former studies used CM as a chemoattractant, whereas the latter used FBS. As we now show, both of these prior observations are correct; myopodin suppresses the motility of PC3 cells in response to CM but promotes migration under FBS conditions (Figure 2) . Transwell migration assays indicated that myopodin mediates these effects by altering the chemokinetic response of PC3 cells to FBS, which refers to a change in cell motility in response to soluble factors in the absence of a chemical gradient (23) . The profound effects of myopodin on chemokinesis were also reflected in the overall invasion potential of the cell population through Matrigel. In the presence of CM, myopodin suppressed both cell migration and invasion by ~40-50%, whereas myopodin increased migration and invasion by 3.5-to 5-fold in response to FBS stimulation ( Figure 3 ). Myopodin therefore affected migration and invasion to approximately the same degree, regardless of whether it was promoting or inhibiting these processes, suggesting that myopodin affects cell invasion primarily by altering cell motility. The basis for these effects remains to be determined, but one possibility is that myopodin affects the balance between intrinsically random versus directionally persistent PC3 cell migration. A similar effect was noted previously in PC3 cells in response to insulin-like growth factor-1 stimulation, where Rho C activity converts persistent linear migration to random, non-linear migration (24) . Regardless of the actual mechanism, the present results clearly indicate that myopodin can have diametrically opposed effects on the response of PC3 cells to different external stimuli.
Truncation analysis indicated that sequences in the extended N-terminus conserved in the long myopodin isoforms and the unique 9-residue C-terminus present in the △N-MYO1 isoform both contribute to the migration effects of myopodin ( Figure 5 ). It was only when both termini were deleted (the △C/△N-MYO construct) that a dramatic reduction in the cell motility response was observed. Previous interaction and deletion analyses using the human △N-MYO1 isoform identified several regions that interact with a number of cellular partners, including zyxin, integrin-linked kinase (ILK), α-actinin and filamin (7, 8, 16) . The mouse homolog of this isoform also contains an actin binding site (15) . However, all of these interaction sites are contained within the central conserved region of myopodin, which is retained in the △C/△N-MYO construct. No interaction studies have been performed with the extended myopodin isoforms that contain the N-terminal PDZ domain, and no studies have specifically used the unique C-termini of the myopodin isoforms as bait, two regions we have shown to be important for the migration phenotypes of myopodin-expressing cells. Further interaction studies based on the myopodin termini may therefore identify additional partners important for regulating cancer cell migration.
Much of the confusion on whether myopodin promotes or inhibits cell migration reflects the differential effects of generic migration stimuli on the inherent motility of PC3 cells. It is clear that PC3 cells respond to a diverse range of internal and external signals via differential activation of both Rac and Rho signaling pathways (21, 22, (24) (25) (26) (27) (28) (29) . As we now show, CM is a potent stimulator of PC3 cell migration and induces an elongated morphology in all cells, while cells tended to assume a rounded morphology and displayed low motility in response to 10% FBS (Figure 2 ). These differences in morphology and migration are reminiscent of changes that occur when the relative balance of The migration of PC3 cells, mock-transduced or transduced with vectors expressing the indicated myopodin isoforms, through transwell membranes in response to the indicated migration stimulus (CM or FBS) was determined as described in Figure 2 . Results are reported as the mean fold change in cells migrated relative to mock-transduced cells ± SEM from three independent experiments performed in duplicate. Statistically significant differences between paired samples are indicated (*P < 0.05; **P < 0.01).
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activated forms of the Rho family of small GTPases is shifted. For instance, increasing concentrations of activated Rac GTPase promotes symmetrical lamellipodia formation and decreases directional migration, whereas increasing activation of Rho-GTPase induces cell polarization and increased lamellipodia at the leading cell edge to promote persistent directional migration (20, 30) . The observation that inhibiting ROCK, a downstream effector of Rho, dramatically impaired the ability of CM to stimulate cell migration ( Figure 6A ) indicates CM activates Rho pathways in PC3 cells and is consistent with the elongated morphology and high motility of cells under these conditions. Conversely, FBS had only a modest effect on Rho-GTP levels in mock-transduced cells ( Figure 6B ), this level of activation was insufficient to promote cell migration ( Figure 6A) , and a ROCK inhibitor had no effect on PC3 cell migration in the presence of FBS ( Figure 6A ). Thus, substantial differences exist in the complex signaling changes induced in mock-transduced PC3 cells by CM and FBS, at least some of which involve differential effects on Rho signaling pathways.
Most importantly, the effects of myopodin on PC3 cell migration in response to the different external stimuli reflect altered activation of ROCK-dependent and ROCK-independent signaling pathways. Under conditions that promote a ROCK-dependent chemokinetic response in PC3 cells (i.e. CM), myopodin modestly suppresses cell migration. Why myopodin only partially inhibits the ROCK-dependent activation of PC3 cells by CM is unclear. Previous studies, using clonal isolates of myopodin-expressing PC3 cells, showed either no effect of myopodin on cell migration or ~50-80% decrease in migration (6, 8) , in comparison with the ~20-40% decrease in migration we observed (Figures 2A and 6A) . Myopodin, therefore, displays a variable ability to partially block the potent activation of ROCK-dependent migration stimulated by CM. In contrast, a weak migration stimulus (i.e. FBS) renders cells responsive to a myopodin-dependent chemokinetic response that correlates with ~4-fold increases in Rho-GTP levels and cell migration ( Figure 6A and 6B), and the migration response is reduced by ~40% in the presence of a ROCK inhibitor ( Figure 6C and 6D) . Myopodin can, therefore, promote cell migration via activation of the Rho-ROCK signaling pathway. Based solely on the ROCK inhibitor results, we cannot exclude the possible additional involvement of the Rho effector kinase PRK that is also inhibited, at least in vitro, by similar concentrations of the Y-27632 inhibitor (17) . However, the cell morphology changes are certainly consistent with well-described alterations to the Rho-ROCK signaling pathway. Rho C activation has also been shown to promote PC3 cell migration via increased directional motility toward a chemoattractant and decreased linear random migration (24, 25) . Such is not the case for myopodin, which clearly promotes a chemokinetic, rather than a chemotactic, response in PC3 cells (Supplementary Table 1 , available at Carcinogenesis Online).
The ROCK inhibitor results also suggest that the motility response of PC3 cells to myopodin is not entirely ROCK-dependent, since the inhibitor effectively eliminated phosphorylation of the myosin light chain target of ROCK while migration was only inhibited by 40% ( Figure 6D) . Coupled with the observation that inhibiting Rac activation has no effect on the stimulatory effect of myopodin on cell migration (Supplementary Figure 1 , available at Carcinogenesis Online), it is now apparent that the effects of myopodin on cell migration involves more that just alteration of the complex interplay between the Rac and Rho signaling pathways. The mouse, chicken and rabbit homologs of myopodin have actin binding, polymerization and bundling activity (15,31,32) . Myopodin also binds to integrin-linked Myopodin effects on cell migration kinase and zyxin, both of which are important players in focal adhesion complexes (7, 8) . Thus, the effects of myopodin on cell migration may well reflect additional Rho-and Rac-independent changes on the actin cytoskeletal network and/or focal adhesion dynamics.
The strong correlation between invasive tumor development and the loss of expression suggests that myopodin may function as a tumor suppressor. Overexpression of myopodin in a naturally invasive prostate cancer cell line can also reduce the metastatic potential of PC3 cells in vivo (6) . A straightforward explanation for this phenotype is the ability of myopodin to suppress cell motility in response to certain external stimuli. The present results, however, caution against such an oversimplified interpretation of the existing data. Diverse signals in the tissue microenvironment promote, inhibit and coordinate the migration of both normal and neoplastic cells. As we show, myopodin can promote or repress cell motility, either or both of which could provide an explanation for the role of myopodin as a tumor suppressor. For example, the coordinated, directional migration of epithelial cells is required to maintain the epithelium (33) . If myopodin naturally functions to promote epithelial cell migration, then loss of myopodin expression would result in disruption of the epithelium and associated basal lamina that serve as barriers to tumor cell invasion. The function of myopodin as a tumor suppressor might, therefore, reflect roles in promoting and/or inhibiting cell migration. Further studies are clearly needed to determine how the complex roles of myopodin in regulating the cellular response to external migration stimuli affect tissue homeostasis and tumor cell invasion.
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